There is actually a huge business opportunity here for a middleman to take on some of the risk. The middleman would evaluate patients and make a decision to guarantee payment based upon the patient profile. They guarantee to the doc they will pay if the MAC rejects the claim or delays payment.
Trick is I'm not sure some % of the $5800 provides enough money to create such a business. Not sure you could take a piece of DNDN's $93,000 for the service as your guarantee program could muck up the laws against DNDN doing this.
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr